30

Oct, 2021

ECNP 2021 | Daridorexant: a breakthrough for insomnia treatment in Europe?

By: | Tags: | Comments: 0

Diego Garcia-Borreguero, MD, PhD, Sleep Research Institute, Madrid, Spain, talks of the implications of the positive Phase III trials of daridorexant, a novel dual orexin receptor antagonist (DORAs), for the treatment of insomnia. Two pivotal Phase III studies investigating the safety and efficacy of daridorexant at four dose levels found a significant dose-response relationship, with 50mg shown to be effective for reducing latency to persistent sleep, reducing wake after sleep…

SABER MÁS